TSNDF · TerrAscend Corp.
Market Cap
$199.11M
Shares
309.18M
Volume · Oct 5
695.79K
Avg daily vol (3M)
255.63K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.51
Open$0.51
Day$0.51–0.54
52W close$0.38–1.32
Avg vol 30d298K
Short int980K · 0.3% float · 3.1d
Short vol30%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$263.91M
Trailing 12 months
Net income (TTM)
−$37.01M
Trailing 12 months
Revenue growth YoY
+3.3%
Year over year
Operating margin
16.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
9.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+3.4%
Year over year · more shares
Price change (1Y)
-41.6%
Trailing year
Short interest
0.3%
Latest settlement · 3.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−22%
below
Price vs 50-day avg
−14%
below
RSI (14)
35
neutral
MACD trend
Negative
52-week position
14%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−26%
trailing
6-month return
−19%
trailing
YTD return
−29%
this year
Relative strength
−31%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.32% of float · ▼ -7.4% MoM · 3.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score
34
low risk · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
52%
expanding
EPS growth
−4%
Y/Y
Free cash flow
$12.9M
Balance sheet
$188.0M
net debt
Quant / Vol
risk profile
Volatility
159%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
9.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Aug 6, 2026
Year-over-year revenue growth
· Q3
2% – 3%
Prior guidance
period ended
· from the Earnings Call filed May 7, 2026
Year-over-year revenue growth
· Q2
2% – 3%
Guided vs delivered
· last 2 settled
Net Revenue
full year 2023
guided $320M
$250.51M
Miss −21.7%
Net Revenue
2023 fourth quarter
guided $89M
$19.75M
Miss −77.8%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−22%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
35
Neutral
MACD trend
Negative
Bearish
52-week position
14%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.32% of float · ▼ -7.4% MoM · 3.1 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $1 · 14%
Range high $1
vs 200-day avg -22%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA from continuing operations non-GAAP | $17.7M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP EBITDA from continuing operations 14.76M
+829K Share-based compensation
+1.17M Loss (gain) on fair value of derivative liabilities
+333K Unrealized and realized foreign exchange loss (gain)
+271K Unrealized and realized loss (gain) on investments
-1K (Gain) loss on lease termination
+0K Gain from revaluation of contingent consideration
+302K Other one-time items
= Adjusted EBITDA from continuing operations 17.66M
|
|||
| Adjusted EBITDA Margin from continuing operations non-GAAP | 26.3% | Q2 2026 | — |
| EBITDA from continuing operations non-GAAP | $14.76M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net loss from continuing operations -10.06M
+11.59M Provision for income taxes
+9.35M Finance expenses
+3.88M Amortization and depreciation
= EBITDA from continuing operations 14.76M
|
|||
| Free Cash Flow non-GAAP | $5.7M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities - continuing operations 7.39M
-1.64M Capital expenditures for property and equipment
= Free Cash Flow 5.75M
|
|||
| Free Cash Flow Yield non-GAAP | 9.9% | Trailing Twelve Months Ended June 30, 2026 | — |
| Market share in Maryland | 6% | Q2 2026 | — |
| Operating Cash Flow Yield non-GAAP | 12.5% | Trailing Twelve Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TSNDF
this stock
TerrAscend Corp.
|
$199.11M | -28.8% | -2.8% | — | 0.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.2% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +27.1% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -12.8% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TSNDF | -15.9% | -25.7% | -19.2% | +1.6% | -28.8% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -17.1% | -26.3% | -30.8% | 0.0% | -42.4% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
shares 9.35M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.